AGREEMENTAgreement • July 17th, 2009 • Prospect Venture Partners III L P • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of Somaxon Pharmaceuticals, Inc.
AGREEMENTSchedule 13g Agreement • February 10th, 2014 • Prospect Venture Partners III L P • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of KYTHERA Biopharmaceuticals, Inc.
AGREEMENTSchedule 13g Agreement • March 8th, 2011 • Prospect Venture Partners III L P • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of Insmed Incorporated.
AGREEMENTSchedule 13g Agreement • February 11th, 2011 • Prospect Venture Partners III L P • Services-commercial physical & biological research
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of Complete Genomics, Inc.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 15th, 2006 • Prospect Venture Partners III L P • Pharmaceutical preparations • New York
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of the 6th day of June 2005, by and between Critical Therapeutics, Inc. (the “Company”), a corporation organized under the laws of the State of Delaware, with its principal offices at 60 Westview Street, Lexington, Massachusetts 02421, and the purchaser whose name and address is set forth on the signature page hereof (the “Purchaser”).
AGREEMENTSchedule 13g Agreement • February 10th, 2014 • Prospect Venture Partners III L P • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of Insmed Incorporated.
AGREEMENTSchedule 13g Agreement • January 28th, 2013 • Prospect Venture Partners III L P • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of KYTHERA Biopharmaceuticals, Inc.
AGREEMENTAgreement • February 11th, 2010 • Prospect Venture Partners III L P • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of Somaxon Pharmaceuticals, Inc.
AGREEMENTSchedule 13g Agreement • January 26th, 2016 • Prospect Venture Partners III L P • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of KYTHERA Biopharmaceuticals, Inc.
